How is corticolimbic vulnerability to tau pathology as a continuous trait associated with clinicopathologic heterogeneity and glial activation patterns in neuropathologically diagnosed Alzheimer disease (AD)? The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.